NYSE:HAE - Haemonetics Stock Price, Price Target & More

$76.08 +0.34 (+0.45 %)

(As of 04/22/2018 06:37 AM ET)

Previous Close$76.08

Today's Range$75.51 - $76.38

52-Week Range$38.47 - $76.38

Volume373,525 shs

Average Volume372,416 shs

Market Capitalization$4.07 billion

P/E Ratio41.80

Dividend YieldN/A

Beta0.89

About Haemonetics (NYSE:HAE)

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products. The company also offers hospital products comprising TEG thrombelastograph hemostasis analyzer system, a blood diagnostic instrument that measure a patient's hemostasis or the ability to form and maintain blood clots; Cell Saver system, a surgical blood salvage system for cardiovascular surgeries; and OrthoPAT surgical blood salvage systems for orthopedic procedures. In addition, it offers SafeTrace Tx, a software solution that manages blood product inventory and transfusion, as well as performs patient cross-matching; and BloodTrack suite of solutions for managing, tracking, and controlling blood products from the hospital blood center through to transfusion to the patient. The company markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations, and national health organizations through its direct sales force, as well as independent distributors. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryHealth Care Supplies

SectorMedical

SymbolNYSE:HAE

CUSIP40502410

Webwww.haemonetics.com

Phone781-848-7100

Debt

Debt-to-Equity Ratio0.14%

Current Ratio1.82%

Quick Ratio1.33%

Price-To-Earnings

Trailing P/E Ratio41.80

Forward P/E Ratio40.90

P/E Growth3.32

Sales & Book Value

Annual Sales$886.12 million

Price / Sales4.59

Cash Flow$3.2513 per share

Price / Cash23.40

Book Value$14.22 per share

Price / Book5.35

Profitability

EPS (Most Recent Fiscal Year)$1.53

Net Income$-26,260,000.00

Net Margins-1.94%

Return on Equity12.39%

Return on Assets7.66%

Miscellaneous

Employees3,107

Outstanding Shares53,450,000

How to Become a New Pot Stock Millionaire

Haemonetics (NYSE:HAE) Frequently Asked Questions

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

How will Haemonetics' stock buyback program work?

Haemonetics announced that its Board of Directors has approved a stock repurchase plan on Tuesday, February 6th 2018, which allows the company to buyback $260,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board believes its stock is undervalued.

How were Haemonetics' earnings last quarter?

Haemonetics (NYSE:HAE) issued its quarterly earnings results on Tuesday, February, 6th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.44 by $0.18. The medical instruments supplier had revenue of $234.04 million for the quarter, compared to analysts' expectations of $227.79 million. Haemonetics had a negative net margin of 1.94% and a positive return on equity of 12.39%. The firm's revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.43 earnings per share. View Haemonetics' Earnings History.

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Haemonetics.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics updated its FY18 earnings guidance on Tuesday, February, 6th. The company provided EPS guidance of $1.80-1.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.70.

What price target have analysts set for HAE?

6 equities research analysts have issued 12-month price objectives for Haemonetics' stock. Their forecasts range from $50.00 to $80.00. On average, they anticipate Haemonetics' stock price to reach $70.00 in the next year. View Analyst Ratings for Haemonetics.

Who are some of Haemonetics' key competitors?

Some companies that are related to Haemonetics include Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Globus Medical (GMED), Cantel Medical (CMD), Penumbra (PEN), NuVasive (NUVA), Nevro (NVRO), Merit Medical Systems (MMSI), NovoCure (NVCR), Mazor Robotics (MZOR), Irhythm Technologies (IRTC), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR) and Glaukos (GKOS).

Who are Haemonetics' key executives?

Haemonetics' management team includes the folowing people:

Mr. Christopher Simon, Chief Exec. Officer, Pres and Director (Age 54)
Mr. William P. Burke, Chief Financial Officer and Exec. VP
Mr. Neil Ryding, Exec. VP of Global Operations (Age 57)
Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 41)
Mr. Gerard J. Gould, VP of Investor Relations (Age 64)

Has Haemonetics been receiving favorable news coverage?

News articles about HAE stock have trended positive this week, Accern reports. The research group scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Haemonetics earned a news impact score of 0.44 on Accern's scale. They also gave media headlines about the medical instruments supplier an impact score of 45.71 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $76.08.

How big of a company is Haemonetics?

Haemonetics has a market capitalization of $4.07 billion and generates $886.12 million in revenue each year. The medical instruments supplier earns $-26,260,000.00 in net income (profit) each year or $1.53 on an earnings per share basis. Haemonetics employs 3,107 workers across the globe.

How can I contact Haemonetics?

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]

MarketBeat Community Rating for Haemonetics (HAE)

Community Ranking:		2.0 out of 5 ( )
Outperform Votes:		177 (Vote Outperform)
Underperform Votes:		261 (Vote Underperform)
Total Votes:		438

MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe HAE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HAE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Haemonetics (NYSE:HAE) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

6 Wall Street analysts have issued ratings and price targets for Haemonetics in the last 12 months. Their average twelve-month price target is $70.00, suggesting that the stock has a possible downside of 7.99%. The high price target for HAE is $80.00 and the low price target for HAE is $50.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.67	2.67	2.67	2.50
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$70.00	$70.00	$56.60	$44.60
Price Target Upside:	7.99% downside	2.13% upside	9.73% downside	3.84% downside

Haemonetics (NYSE:HAE) Consensus Price Target History

Price Target History for Haemonetics (NYSE:HAE)

Haemonetics (NYSE:HAE) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/7/2018	Morgan Stanley	Boost Price Target	Overweight -> Overweight	$74.00 -> $77.00	High
2/7/2018	Barrington Research	Reiterated Rating	Outperform -> Outperform	$57.00 -> $71.00	High
2/7/2018	JMP Securities	Reiterated Rating	Outperform	$72.00	High
2/7/2018	Jefferies Group	Reiterated Rating	Buy	$80.00	High
1/2/2018	Raymond James	Upgrade	Underperform -> Market Perform		High
11/8/2017	Craig Hallum	Reiterated Rating	Hold	$40.00 -> $50.00	N/A
11/7/2016	BTIG Research	Reiterated Rating	Neutral		N/A
11/7/2016	Benchmark	Boost Price Target	Hold	$32.00 -> $34.00	N/A
10/14/2016	Off Wall Street	Initiated Coverage	Sell	$24.00	N/A
9/20/2016	CJS Securities	Downgrade	Market Outperform -> Market Perform	$35.00	N/A
8/15/2016	Sidoti	Downgrade	Buy -> Neutral	$39.00	N/A
5/16/2016	Goldman Sachs	Upgrade	Sell -> Neutral	$29.00	N/A

(Data available from 4/22/2016 forward)

Haemonetics (NYSE:HAE) Earnings History and Estimates Chart

Earnings by Quarter for Haemonetics (NYSE:HAE)

Haemonetics (NYSE:HAE) Earnings Estimates

2018 EPS Consensus Estimate: $1.58
2019 EPS Consensus Estimate: $2.08

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$0.25	$0.37	$0.30
Q2 2018	3	$0.38	$0.47	$0.44
Q3 2018	3	$0.41	$0.45	$0.43
Q4 2018	2	$0.40	$0.43	$0.42
Q1 2019	3	$0.41	$0.46	$0.44
Q2 2019	3	$0.51	$0.56	$0.54
Q3 2019	3	$0.54	$0.63	$0.58
Q4 2019	3	$0.49	$0.54	$0.52

Haemonetics (NYSE HAE) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/8/2018		$0.43					N/A
2/6/2018	Q3 2018	$0.44	$0.62	$227.79 million	$234.04 million	View	Listen
11/7/2017	Q2 2018	$0.41	$0.48	$219.12 million	$225.40 million	View	N/A
8/7/2017	Q1 2018	$0.31	$0.33	$211.29 million	$211.00 million	View	Listen
5/8/2017	Q4 2017	$0.37	$0.39	$215.06 million	$228.10 million	View	Listen
2/6/2017	Q317	$0.40	$0.43	$220.00 million	$227.80 million	View	Listen
11/7/2016	Q217	$0.35	$0.46	$210.72 million	$220.30 million	View	Listen
8/1/2016	Q117	$0.28	$0.25	$205.41 million	$210.00 million	View	Listen
5/2/2016	Q416	$0.46	$0.37	$245.08 million	$243.20 million	View	Listen
2/1/2016	Q316	$0.46	$0.48	$237.37 million	$233.40 million	View	Listen
11/4/2015	Q216	$0.40	$0.44	$226.50 million	$219.70 million	View	Listen
7/27/2015	Q116	$0.33	$0.35	$215.62 million	$213.40 million	View	Listen
4/27/2015	Q415	$0.51	$0.47	$239.20 million	$226.50 million	View	Listen
1/29/2015	Q315	$0.51	$0.53	$235.45 million	$231.80 million	View	Listen
11/3/2014	Q215	$0.45	$0.47	$229.90 million	$227.60 million	View	Listen
7/30/2014	Q115	$0.35	$0.38	$215.85 million	$224.49 million	View	Listen
4/28/2014	Q414	$0.58	$0.46	$244.87 million	$241.00 million	View	Listen
1/27/2014	Q314	$0.61	$0.61	$243.71 million	$242.10 million	View	Listen
10/28/2013	Q214	$0.57	$0.66	$239.51 million	$235.80 million	View	Listen
7/29/2013	Q1 2014	$0.47	$0.46	$232.98 million	$219.50 million	View	Listen
5/1/2013	Q4 2013	$0.46	$0.48	$249.33 million	$249.90 million	View	Listen
1/30/2013	Q3 2013	$0.47	$0.50	$251.93 million	$247.40 million	View	Listen
10/29/2012	Q213	$0.77	$0.90	$223.47 million	$218.18 million	View	N/A
8/1/2012		$0.71	$0.55			View	N/A
4/30/2012		$0.83	$0.80			View	N/A
1/30/2012		$0.80	$0.86			View	N/A
10/31/2011		$0.77	$0.72			View	N/A
8/1/2011		$0.77	$0.65			View	N/A
5/2/2011		$0.83	$0.85			View	N/A
1/31/2011		$0.82	$0.89			View	N/A
11/1/2010	Q2 2011	$0.38	$0.40			View	N/A
8/2/2010	Q1 2011	$0.36	$0.37			View	N/A
5/4/2010	Q4 2010	$0.38	$0.38			View	N/A
2/1/2010	Q3 2010	$0.36	$0.35			View	N/A
11/2/2009	Q2 2010	$0.33	$0.34			View	N/A
8/3/2009	Q1 2010	$0.33	$0.35			View	N/A
5/4/2009	Q4 2009	$0.32	$0.32			View	N/A
2/2/2009	Q3 2009	$0.31	$0.32			View	N/A
10/27/2008	Q2 2009	$0.28	$0.29			View	N/A
8/1/2008	Q1 2009	$0.28	$0.29			View	N/A
5/1/2008	Q4 2008	$0.29	$0.29			View	N/A
1/31/2008	Q3 2008	$0.27	$0.29			View	N/A

(Earnings results data provided by Zacks Investment Research)

Haemonetics (NYSE:HAE) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Haemonetics (NYSE HAE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%

Insider Trading History for Haemonetics (NYSE:HAE)

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Haemonetics (NYSE HAE) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/6/2018	Dan Goldstein	VP	Sell	518	$54.65	$28,308.70	4,002
3/6/2018	Jacqueline Scanlan	SVP	Sell	114	$72.23	$8,234.22
3/6/2018	Michelle L. Basil	EVP	Sell	389	$72.23	$28,097.47
1/2/2018	Mark W Kroll	Director	Sell	7,118	$63.00	$448,434.00	33,881
12/1/2017	Pedro P Granadillo	Director	Sell	7,118	$57.06	$406,153.08	31,663
11/16/2017	Ronald G Gelbman	Director	Sell	5,440	$56.69	$308,393.60
11/14/2017	Willaim P Burke	CFO	Sell	13,193	$54.04	$712,949.72	27,227
11/13/2017	Dan Goldstein	CAO	Sell	4,691	$54.93	$257,676.63	3,747
11/10/2017	Susan Bartlett Foote	Director	Sell	16,926	$54.19	$917,219.94	27,313
5/22/2017	Ronald Merriman	Director	Sell	17,471	$40.33	$704,605.43	24,925
12/12/2016	Ronald G Gelbman	Director	Sell	5,683	$40.30	$229,024.90	49,688
8/17/2016	Ronald Merriman	Director	Sell	4,337	$35.14	$152,402.18	22,088
8/4/2016	Christopher Simon	CEO	Buy	60,000	$35.00	$2,100,000.00
10/26/2015	Byron Selman	Insider	Sell	344	$32.13	$11,052.72	12,010
10/26/2015	Christopher J Lindop	CFO	Sell	436	$32.13	$14,008.68	45,350
10/26/2015	Sandra Jesse	EVP	Sell	778	$32.13	$24,997.14	20,096
10/26/2015	Susan M Hanlon	VP	Sell	497	$32.13	$15,968.61	20,464
9/15/2015	Brian Concannon	CEO	Sell	6,569	$35.15	$230,900.35	147,040
9/1/2015	Brian Concannon	CEO	Sell	4,765	$35.63	$169,776.95	147,040
8/20/2015	Christopher J. Lindop	CFO	Sell	4,902	$38.49	$188,677.98	38,188
8/17/2015	Brian Concannon	CEO	Sell	6,569	$39.28	$258,030.32
7/20/2015	Christopher J Lindop	CFO	Sell	4,902	$39.09	$191,619.18
7/15/2015	Brian Concannon	CEO	Sell	6,569	$39.59	$260,066.71
7/6/2015	Peter M Allen	Insider	Sell	30,494	$40.19	$1,225,553.86
7/2/2015	Jonathan White	Insider	Sell	2,385	$41.14	$98,118.90
6/22/2015	Christopher J Lindop	CFO	Sell	4,902	$42.51	$208,384.02
6/15/2015	Brian Concannon	CEO	Sell	6,569	$42.51	$279,248.19
6/10/2015	Susan M Hanlon	VP	Sell	6,000	$43.00	$258,000.00
6/1/2015	Brian Concannon	CEO	Sell	4,765	$41.39	$197,223.35
5/20/2015	Christopher J Lindop	CFO	Sell	4,902	$41.65	$204,168.30
5/1/2015	Brian Concannon	CEO	Sell	4,765	$40.74	$194,126.10
4/20/2015	Christopher J Lindop	CFO	Sell	4,902	$41.55	$203,678.10
4/1/2015	Brian Concannon	CEO	Sell	4,765	$44.51	$212,090.15
3/27/2015	Susan M Hanlon	VP	Sell	7,000	$43.46	$304,220.00
3/20/2015	Christopher J Lindop	CFO	Sell	4,902	$44.26	$216,962.52
3/10/2015	Susan Bartlett Foote	Director	Sell	11,328	$43.84	$496,619.52
3/5/2015	Ronald G Gelbman	Director	Sell	7,707	$44.76	$344,965.32
3/4/2015	Ronald Merriman	Director	Sell	14,258	$43.80	$624,500.40
3/2/2015	Brian Concannon	CEO	Sell	4,765	$44.41	$211,613.65
2/18/2015	Pedro P Granadillo	Director	Sell	11,328	$43.45	$492,201.60
2/2/2015	Brian Concannon	CEO	Sell	4,765	$39.15	$186,549.75
1/2/2015	Brian Concannon	CEO	Sell	4,765	$37.20	$177,258.00
12/1/2014	Brian Concannon	CEO	Sell	4,765	$36.72	$174,970.80
11/3/2014	Brian Concannon	CEO	Sell	4,765	$35.86	$170,872.90
10/13/2014	Peter M Allen	Insider	Sell	36,426	$35.22	$1,282,923.72
8/12/2014	Ronald Merriman	Director	Sell	13,602	$35.76	$486,407.52
8/1/2014	Brian Concannon	CEO	Sell	4,380	$35.27	$154,482.60
7/7/2014	Pedro P Granadillo	Director	Sell	5,837	$35.97	$209,956.89
6/12/2014	Ronald G Gelbman	Director	Sell	9,184	$34.00	$312,256.00
6/6/2014	Pedro P Granadillo	Director	Sell	5,837	$34.69	$202,485.53
5/12/2014	Susan Bartlett Foote	Director	Sell	9,184	$33.16	$304,541.44	9,939
5/7/2014	Pedro Granadillo	Director	Sell	5,837	$31.14	$181,764.18	14,901
5/1/2014	Brian Concannon	CEO	Sell	4,600	$30.01	$138,046.00	130,307
4/28/2014	Peter Allen	Insider	Sell	30,000	$30.70	$921,000.00	28,950
4/7/2014	Pedro Granadillo	Director	Sell	5,837	$31.98	$186,667.26	14,901
4/1/2014	Brian Concannon	CEO	Sell	4,600	$32.71	$150,466.00	130,307
3/6/2014	Ronald Gelbman	Director	Sell	12,000	$36.17	$434,040.00	39,173
3/3/2014	Brian Concannon	CEO	Sell	4,600	$36.36	$167,256.00	130,307
2/18/2014	Susan Hanlon	VP	Sell	3,690	$39.00	$143,910.00	16,905
2/7/2014	Jonathan White	Insider	Sell	1,880	$38.66	$72,680.80	25,166
2/3/2014	Brian Concannon	CEO	Sell	7,600	$37.63	$285,988.00	130,307
1/27/2014	Susan Hanlon	VP	Sell	3,206	$38.37	$123,014.22	16,905
1/10/2014	Susan Hanlon	VP	Sell	4,000	$41.80	$167,200.00	16,905
1/2/2014	Brian Concannon	CEO	Sell	7,600	$41.58	$316,008.00	130,307
12/16/2013	Susan Hanlon	VP	Sell	4,000	$43.50	$174,000.00	16,905
12/9/2013	Susan Hanlon	VP	Sell	3,138	$43.07	$135,153.66	16,905
12/2/2013	Brian Concannon	CEO	Sell	7,600	$42.31	$321,556.00	130,307
11/12/2013	Michael Kelly	Insider	Sell	61,400	$39.70	$2,437,580.00	10,987
11/1/2013	Brian Concannon	CEO	Sell	7,600	$39.96	$303,696.00
10/14/2013	Michael Kelly	Insider	Sell	1,400	$40.41	$56,574.00	11,337
9/13/2013	Michael Kelly	Insider	Sell	1,400	$40.36	$56,504.00	11,337
9/3/2013	Brian Concannon	CEO	Sell	13,000	$39.87	$518,310.00	115,798
8/1/2013	Brian Concannon	CEO	Sell	13,000	$42.24	$549,120.00
7/12/2013	Michael P Kelly	Insider	Sell	1,400	$44.10	$61,740.00
7/1/2013	Brian Concannon	CEO	Sell	13,000	$41.87	$544,310.00
6/18/2013	Christopher J Lindop	CFO	Sell	68,628	$42.50	$2,916,690.00
6/14/2013	Michael P Kelly	Insider	Sell	1,400	$42.17	$59,038.00
6/3/2013	Brian Concannon	CEO	Sell	13,000	$41.15	$534,950.00
5/21/2013	Christopher J Lindop	CFO	Sell	42,882	$42.00	$1,801,044.00
5/14/2013	Michael P Kelly	Insider	Sell	1,400	$39.66	$55,524.00
5/1/2013	Brian Concannon	CEO	Sell	13,000	$38.66	$502,580.00
12/3/2012	Brian Concannon	CEO	Sell	13,000	$40.75	$529,750.00
11/12/2012	Pedro P Granadillo	Director	Sell	16,000	$80.40	$1,286,400.00
9/4/2012	Brian Concannon	CEO	Sell	6,500	$73.68	$478,920.00
9/4/2012	Christopher J Lindop	CFO	Sell	61,783	$74.34	$4,592,948.22

(Data available from 1/1/2013 forward)

Haemonetics (NYSE HAE) News Headlines

Source:

Date	Headline
	Teleflex (TFX) versus Haemonetics (HAE) Critical Contrast www.americanbankingnews.com - April 18 at 1:20 AM
	BidaskClub Downgrades Haemonetics (HAE) to Strong Sell www.americanbankingnews.com - April 15 at 1:17 PM
	Haemonetics (HAE) Lifted to Sell at BidaskClub www.americanbankingnews.com - April 12 at 6:15 PM
	$224.57 Million in Sales Expected for Haemonetics Co. (HAE) This Quarter www.americanbankingnews.com - April 12 at 4:37 AM
	Haemonetics Co. (HAE) Receives Average Recommendation of "Hold" from Analysts www.americanbankingnews.com - April 12 at 1:29 AM
	Haemonetics (HAE) Lifted to "Buy" at Zacks Investment Research www.americanbankingnews.com - April 11 at 8:27 PM
	Haemonetics Rides High on Plasma, Blood Center Remains Weak finance.yahoo.com - April 11 at 4:28 PM
	Haemonetics (HAE) Lowered to "Sell" at Zacks Investment Research www.americanbankingnews.com - April 11 at 10:25 AM
	Insider Selling: Haemonetics Co. (HAE) VP Sells 518 Shares of Stock www.americanbankingnews.com - April 10 at 7:31 PM
	Haemonetics Sets Date for Publishing Fourth Quarter Fiscal 2018 Results: May 8, 2018 finance.yahoo.com - April 10 at 9:54 AM
	Zacks: Analysts Anticipate Haemonetics Co. (HAE) Will Announce Earnings of $0.43 Per Share www.americanbankingnews.com - April 10 at 5:24 AM
	Haemonetics (HAE) Upgraded to Strong-Buy by ValuEngine www.americanbankingnews.com - April 10 at 12:33 AM
	Haemonetics' Plasma Tool Enhancement Gets 510(K) Clearance finance.yahoo.com - April 2 at 4:29 PM
	Haemonetics' Plasma Tool Enhancement Gets 510(K) Clearance feeds.benzinga.com - April 2 at 1:52 PM
	Barrington Research Increases Haemonetics (HAE) Price Target to $57.00 www.americanbankingnews.com - April 1 at 9:40 AM
	Haemonetics (HAE) PT Raised to $51.00 at Morgan Stanley www.americanbankingnews.com - March 31 at 5:28 PM
	Haemonetics (HAE) Raised to Overweight at Morgan Stanley www.americanbankingnews.com - March 31 at 12:54 PM
	Head to Head Analysis: Sientra (SIEN) versus Haemonetics (HAE) www.americanbankingnews.com - March 29 at 10:19 AM
	Haemonetics Announces Regulatory Clearances of NexSys PCS™ Enhanced Software ... www.prnewswire.com - March 29 at 9:53 AM
	Haemonetics Announces Regulatory Clearances of NexSys PCS™ Enhanced Software with YES™ Technology finance.yahoo.com - March 28 at 9:44 AM
	Why Should You Add Haemonetics (HAE) to Your Portfolio Now? finance.yahoo.com - March 26 at 4:19 PM
	Haemonetics (HAE) Stock Rating Reaffirmed by Jefferies Group www.americanbankingnews.com - March 25 at 7:44 AM
	Zacks: Analysts Expect Haemonetics Co. (HAE) to Announce $0.43 Earnings Per Share www.americanbankingnews.com - March 24 at 5:24 AM
	It Is Still Not Too Late To Pick Up Haemonetics In CY 2018 seekingalpha.com - March 21 at 10:40 AM
	The Hospital Business Remains 1of HAE’s Key Growth Drivers finance.yahoo.com - March 21 at 10:40 AM
	HAE Focuses on Revitalizing Cell Salvage Business in Fiscal 2018 finance.yahoo.com - March 21 at 10:40 AM
	Plasma Remains an Attractive Business for HAE finance.yahoo.com - March 20 at 4:19 PM
	Haemonetics Co. (HAE) to Post Q1 2019 Earnings of $0.41 Per Share, William Blair Forecasts www.americanbankingnews.com - March 20 at 11:12 AM
	Plasma Continues to Drive Strong Growth for HAE in Fiscal 2018 finance.yahoo.com - March 20 at 9:41 AM
	Cerus (CERS) Looks Good: Stock Adds 9.5% in Session finance.yahoo.com - March 19 at 9:41 AM
	Haemonetics Co. (HAE) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - March 18 at 1:36 AM
	Analyzing K2M Group (KTWO) and Haemonetics (HAE) www.americanbankingnews.com - March 11 at 1:22 AM
	3 Stocks to Gain as Trump Pulls Plug on Infamous MedTech Tax finance.yahoo.com - March 9 at 5:27 PM
	Haemonetics Co. (HAE) Expected to Announce Quarterly Sales of $223.09 Million www.americanbankingnews.com - March 9 at 2:41 PM
	Haemonetics Co. (HAE) EVP Sells $28,097.47 in Stock www.americanbankingnews.com - March 8 at 7:27 PM
	Haemonetics (HAE) Up 4.2% Since Earnings Report: Can It Continue? finance.yahoo.com - March 8 at 5:19 PM
	$0.43 Earnings Per Share Expected for Haemonetics Co. (HAE) This Quarter www.americanbankingnews.com - March 7 at 1:16 AM
	Schroder Investment Management Group Cuts Holdings in Haemonetics Co. (HAE) www.americanbankingnews.com - March 6 at 9:48 AM
	Rhumbline Advisers Has $7.14 Million Stake in Haemonetics Co. (HAE) www.americanbankingnews.com - March 6 at 9:02 AM
	BlackRock Inc. Raises Position in Haemonetics Co. (HAE) www.americanbankingnews.com - March 6 at 5:02 AM
	Haemonetics Co. (HAE) Sees Significant Increase in Short Interest www.americanbankingnews.com - March 6 at 1:48 AM
	WINTON GROUP Ltd Invests $6.26 Million in Haemonetics Co. (HAE) Stock www.americanbankingnews.com - March 5 at 4:09 PM
	Haemonetics (HAE) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - March 4 at 5:35 PM
	Teacher Retirement System of Texas Purchases Shares of 18,191 Haemonetics Co. (HAE) www.americanbankingnews.com - March 4 at 7:06 AM
	Head-To-Head Analysis: Haemonetics (HAE) & ICU Medical (ICUI) www.americanbankingnews.com - March 2 at 9:24 PM
	Bogle Investment Management L P DE Grows Position in Haemonetics Co. (HAE) www.americanbankingnews.com - March 2 at 5:06 AM
	Swiss National Bank Raises Position in Haemonetics Co. (HAE) www.americanbankingnews.com - March 1 at 5:42 PM
	Systematic Financial Management LP Lowers Position in Haemonetics Co. (HAE) www.americanbankingnews.com - February 27 at 11:28 AM
	Smith Asset Management Group LP Takes $3.51 Million Position in Haemonetics Co. (HAE) www.americanbankingnews.com - February 26 at 3:22 PM
	Haemonetics Co. (HAE) Shares Sold by Fuller & Thaler Asset Management Inc. www.americanbankingnews.com - February 25 at 2:21 PM

Haemonetics (NYSE:HAE) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Haemonetics (NYSE:HAE) Income Statement, Balance Sheet and Cash Flow Statement

Haemonetics (NYSE HAE) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff